Pharmacy Search
Pharmacy Pharmacy
Most Read Articles
Adjunctive perampanel efficacy, safety in epilepsy hold up over long-term assessment
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
Apixaban may confer survival benefit for COVID-19 inpatients
Pearl Toh, 5 days ago
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Baricitinib shows potential as SLE therapy in phase 2 study
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Podcast: Assoc Prof Yeo Khung Keong talks about the hopes and promises of AI in cardiology

18 Nov 2019
Podcast: Assoc Prof Yeo Khung Keong talks about the hopes and promises of AI in cardiology
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Adjunctive perampanel efficacy, safety in epilepsy hold up over long-term assessment
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
Apixaban may confer survival benefit for COVID-19 inpatients
Pearl Toh, 5 days ago
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Baricitinib shows potential as SLE therapy in phase 2 study
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.